NCT04889118 - Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

January 18, 2023

Study Completion Date

November 1, 2024

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Lenvatinib

Oral capsule

DRUG

Placebo for lenvatinib

Oral capsule

Trial Locations (11)

100036

Beijing Cancer Hospital (0601), Beijing

130021

The First Hospital Of Jilin University (0603), Changchun

200032

Fudan University Shanghai Cancer Center ( Site 0607), Shanghai

210008

Nanjing Drum Tower Hospital (0609), Nanjing

300060

Tianjin Medical University Cancer Institute & Hospital (0606), Tianjin

310018

Sir Run Run Shaw Hospital (0605), Hangzhou

310022

Zhejiang Cancer Hospital ( Site 0608), Hangzhou

350014

Fujian Provincial Cancer Hospital ( Site 0612), Fuzhou

430030

Yunnan Cancer Hospital (0604), Kunming

450003

Henan Cancer Hospital ( Site 0610), Zhengzhou

510000

Sun Yat-Sen University Cancer Center (0602), Guangzhou

All Listed Sponsors

collaborator

Eisai Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY